Formation of dopamine-mediated α-synuclein-soluble oligomers requires methionine oxidation

Free Radical Biology and Medicine

Volumn 46, Issue 10, 2009, Pages 1328-1337

  Leong, Su Ling ^a,b,c   Pham, Chi L L ^a,b,c   Galatis, Denise ^a,b,c   Fodero Tavoletti, Michelle T ^a,b,c   Perez, Keyla ^a,b,c   Hill, Andrew F ^a,b,c   Masters, Colin L ^a,c   Ali, Feda E ^a,b,c   Barnham, Kevin J ^a,b,c   Cappai, Roberto ^a,b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Synuclein; Aggregation; Amyloid; Dopamine; Free radicals; Oligomer; Oxidation; Parkinson disease

Indexed keywords

ALANINE; ALPHA SYNUCLEIN; DOPAMINE; METHIONINE; OLIGOMER; SYNTHETIC PEPTIDE; TYROSYLGLUTAMYLMETHIONYLPROLYLSERINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN MOTIF;

ALPHA-SYNUCLEIN; AMINO ACID MOTIFS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLONING, MOLECULAR; DOPAMINE; HUMANS; LEWY BODIES; METHIONINE; MUTAGENESIS, SITE-DIRECTED; NEURONS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PARKINSON DISEASE; PEPTIDES; PROTEIN BINDING; PROTEIN MULTIMERIZATION; SOLUBILITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 62049085927     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2009.02.009     Document Type: Article

References (34)

1. Lotharius J., and Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 3 (2002) 932-942
2. Gomez-Tortosa E., Newell K., Irizarry M.C., Albert M., Growdon J.H., and Hyman B.T. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 53 (1999) 1284-1291
3. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H.A., Kittel A., and Saitoh T. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14 (1995) 467-475
4. Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., Otero D.A., Kondo J., Ihara Y., and Saitoh T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 11282-11286
5. Iwai A., Yoshimoto M., Masliah E., and Saitoh T. Non-A beta component of Alzheimer's disease amyloid (NAC) is amyloidogenic. Biochemistry 34 (1995) 10139-10145
6. Maroteaux L., Campanelli J.T., and Scheller R.H. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8 (1988) 2804-2815
7. Belin A.C., and Westerlund M. Parkinson's disease: a genetic perspective. FEBS J. 275 (2008) 1377-1383
8. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W.H., Castillo P.E., Shinsky N., Verdugo J.M., Armanini M., Ryan A., Hynes M., Phillips H., Sulzer D., and Rosenthal A. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25 (2000) 239-252
9. Xu J., Kao S.Y., Lee F.J., Song W., Jin L.W., and Yankner B.A. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8 (2002) 600-606
10. Cappai R., Leck S.L., Tew D.J., Williamson N.A., Smith D.P., Galatis D., Sharples R.A., Curtain C.C., Ali F.E., Cherny R.A., Culvenor J.G., Bottomley S.P., Masters C.L., Barnham K.J., and Hill A.F. Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J. 19 (2005) 1377-1379
11. Conway K.A., Rochet J.C., Bieganski R.M., and Lansbury Jr. P.T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294 (2001) 1346-1349
12. Goldberg M.S., and Lansbury Jr. P.T. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?. Nat. Cell Biol. 2 (2000) E115-119
13. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., and Lansbury Jr. P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 571-576
14. Norris E.H., Giasson B.I., Hodara R., Xu S., Trojanowski J.Q., Ischiropoulos H., and Lee V.M. Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J. Biol. Chem. 280 (2005) 21212-21219
15. Mazzulli J.R., Armakola M., Dumoulin M., Parastatidis I., and Ischiropoulos H. Cellular oligomerization of alpha-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence. J. Biol. Chem. 282 (2007) 31621-31630
16. Narhi L., Wood S.J., Steavenson S., Jiang Y., Wu G.M., Anafi D., Kaufman S.A., Martin F., Sitney K., Denis P., Louis J.C., Wypych J., Biere A.L., and Citron M. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem. 274 (1999) 9843-9846
17. Ben-Bassat A., Bauer K., Chang S.Y., Myambo K., Boosman A., and Chang S. Processing of the initiation methionine from proteins: properties of the Escherichia coli methionine aminopeptidase and its gene structure. J. Bacteriol. 169 (1987) 751-757
18. Bradshaw R.A., Brickey W.W., and Walker K.W. N-terminal processing: the methionine aminopeptidase and N alpha-acetyl transferase families. Trends Biochem. Sci. 23 (1998) 263-267
19. Giannakis E., Pacifico J., Smith D.P., Hung L.W., Masters C.L., Cappai R., Wade J.D., and Barnham K.J. Dimeric structures of alpha-synuclein bind preferentially to lipid membranes. Biochim. Biophys. Acta 1778 (2008) 1112-1119
20. Barnham K.J., McKinstry W.J., Multhaup G., Galatis D., Morton C.J., Curtain C.C., Williamson N.A., White A.R., Hinds M.G., Norton R.S., Beyreuther K., Masters C.L., Parker M.W., and Cappai R. Structure of the Alzheimer's disease amyloid precursor protein copper binding domain: a regulator of neuronal copper homeostasis. J. Biol. Chem. 278 (2003) 17401-17407
21. Li H.T., Lin D.H., Luo X.Y., Zhang F., Ji L.N., Du H.N., Song G.Q., Hu J., Zhou J.W., and Hu H.Y. Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein: implication for dopaminergic neurodegeneration. FEBS J. 272 (2005) 3661-3672
22. Klucken J., Shin Y., Masliah E., Hyman B.T., and McLean P.J. Hsp70 reduces alpha-synuclein aggregation and toxicity. J. Biol. Chem. 279 (2004) 25497-25502
23. Hashimoto M., Hsu L.J., Xia Y., Takeda A., Sisk A., Sundsmo M., and Masliah E. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10 (1999) 717-721
24. Hashimoto M., Takeda A., Hsu L.J., Takenouchi T., and Masliah E. Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease. J. Biol. Chem. 274 (1999) 28849-28852
25. Tabrizi S.J., Orth M., Wilkinson J.M., Taanman J.W., Warner T.T., Cooper J.M., and Schapira A.H. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum. Mol. Genet. 9 (2000) 2683-2689
26. LaVoie M.J., and Hastings T.G. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J. Neurosci. 19 (1999) 1484-1491
27. Sulzer D. alpha-Synuclein and cytosolic dopamine: stabilizing a bad situation. Nat. Med. 7 (2001) 1280-1282
28. Vogt W. Oxidation of methionyl residues in proteins: tools, targets, and reversal. Free Radic. Biol. Med. 18 (1995) 93-105
29. Uversky V.N., Yamin G., Souillac P.O., Goers J., Glaser C.B., and Fink A.L. Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. FEBS Lett. 517 (2002) 239-244
30. Li J., Zhu M., Manning-Bog A.B., Di Monte D.A., and Fink A.L. Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J. 18 (2004) 962-964
31. Hokenson M.J., Uversky V.N., Goers J., Yamin G., Munishkina L.A., and Fink A.L. Role of individual methionines in the fibrillation of methionine-oxidized alpha-synuclein. Biochemistry 43 (2004) 4621-4633
32. Wassef R., Haenold R., Hansel A., Brot N., Heinemann S.H., and Hoshi T. Methionine sulfoxide reductase A and a dietary supplement S-methyl-l-cysteine prevent Parkinson's-like symptoms. J. Neurosci. 27 (2007) 12808-12816
33. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., and Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486-489
34. Cappai R., and Barnham K.J. Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity. Neurochem. Res. 33 (2008) 526-532